Boston Urogynecology Associates   Report issue

Academic/Hospital Phase 4
Founded: Cambridge MA United States

Organization Overview

First Clinical Trial
2013
NCT01905137
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Boston Urogynecology Associates

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hematuria (Phase 4)

Hyperkinesis (Phase 4)

Urinary Bladder, Overactive (Phase 4)

Urinary Incontinence, Urge (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 5